Pharmaceutical Stocks Stagned A Recovery in Chiursday’s Morning Session Folling The Federal Reserve’s 25 Basis Point Rate Cut, with the Nifty Pharma Index Climbing 138.70 POINTS to 22,380.5,380.05,380. 0.62 per cent gain from its previous close of 22,241.35. The sector witnessed broad-based buying with 14 stocks Advanceing Against 6 Declines, Reversing Wednsday’s Profit-Booking Trend.

Natco pharma emerged as the top performer, surgging 3.92 per cent to ₹ 890.85, Followed by biocon which gained 2.27 per cent to ₹ 362.40. Gland Pharma Rose 1.76 per cent to ₹ 2,021.90, While Glenmark Pharmaceuticals Advanced 1.38 per cent to ₹ 2,070.60, Recovering from WednsDay’s Decline with Selling Pershes Along with other pharma counters. Sun pharma and aurobindo pharma also contributed positively with Gains of 1.04 per cent and 0.89 per cent respectively.

The Fed’s Dovish Stance is Expected to Attract Foreign Capital to Emerging Markets Including India, potentially Strengthing the Rupee and Benefiting Stock Indices. Rajesh Palviya, SVP – Research at AXIS Securities, Noted that Rate Cut Reflects a cautious approach to support the Labor Market and Cold Lead to Gains in Equites.

Trading Activity remained robust in the pharma space, with biocon leading volume charts at 49.91 lakh shares tradeed, generating a value of ₹ 180.25 Crace. The sector’s recover Comes after Wednessday’s Session Where Metals, FMCG, and Pharma Witnessed Profit-Taking According to Market Analysts.

Published on September 18, 2025